Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dicerna Pharmaceutic (DRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,038,408
  • Shares Outstanding, K 61,810
  • Annual Sales, $ 2,280 K
  • Annual Income, $ -60,050 K
  • 36-Month Beta 2.43
  • Price/Sales 456.02
  • Price/Cash Flow N/A
  • Price/Book 13.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.24
  • Number of Estimates 5
  • High Estimate -0.13
  • Low Estimate -0.28
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +73.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.76 +25.36%
on 09/06/18
17.98 -11.07%
on 09/14/18
+0.09 (+0.57%)
since 08/21/18
3-Month
11.29 +41.63%
on 06/28/18
17.98 -11.07%
on 09/14/18
+2.91 (+22.25%)
since 06/21/18
52-Week
4.19 +281.62%
on 09/22/17
17.98 -11.07%
on 09/14/18
+11.47 (+253.76%)
since 09/21/17

Most Recent Stories

More News
3 Stocks to Watch as Immunotherapy Pushes Biotech Growth

CORAL GABLES, FL / ACCESSWIRE / September 7, 2018 / Data compiled by new data has come out from analyst organizations like Grand View Research which show the biotech sector is expected to break above $727...

DRNA : 15.99 (-4.82%)
GERN : 5.46 (-0.73%)
Dicerna Announces Pricing of Follow-On Public Offering of Common Stock

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the pricing of its underwritten...

DRNA : 15.99 (-4.82%)
Dicerna Announces Proposed Follow-On Public Offering of Common Stock

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the commencement of a proposed...

DRNA : 15.99 (-4.82%)
Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria

--A Detailed Data Readout of the PHYOX Trial is Anticipated in Q4 2018

DRNA : 15.99 (-4.82%)
Dicerna to Participate in Upcoming Investor Conferences

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D.,...

DRNA : 15.99 (-4.82%)
Dicerna Strengthens Board of Directors with Two New Appointments

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointments of J. Kevin...

DRNA : 15.99 (-4.82%)
Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of 33.33% and -13.69%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?...

DRNA : 15.99 (-4.82%)
Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results...

DRNA : 15.99 (-4.82%)
Dicerna to Report Second Quarter 2018 Financial Results and Host Conference Call on August 8, 2018

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release...

DRNA : 15.99 (-4.82%)
Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?

On ACADIA's (ACAD) second-quarter 2018 conference call, investor focus will be on the sales figures of its only marketed drug Nuplazid as well as its pipeline progress.

DRNA : 15.99 (-4.82%)
ACAD : 20.17 (+5.55%)
PCRX : 50.50 (-2.88%)
ADRO : 6.20 (-1.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade DRNA with:

Business Summary

Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 17.40
1st Resistance Point 16.70
Last Price 15.99
1st Support Level 15.55
2nd Support Level 15.10

See More

52-Week High 17.98
Last Price 15.99
Fibonacci 61.8% 12.71
Fibonacci 50% 11.09
Fibonacci 38.2% 9.46
52-Week Low 4.19

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar